Cooley advised the underwriters on Edgewise Therapeutics’ $202.4 million initial public offering of 12,650,000 shares of common stock, which includes the full exercise of the underwriters’ option to purchase additional shares. J.P. Morgan Securities, Goldman Sachs and SVB Leerink acted as joint book-running managers for the offering. Edgewise Therapeutics, whose securities now trade on the Nasdaq Global Market under the symbol EWTX, is a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for rare muscle disorders. Partners Richard Segal, Div Gupta, Ryan Sansom and Brandon Fenn led the Cooley team.